RU2013107095A - Vegf полиморфизм и анти-ангиогенезная терапия - Google Patents

Vegf полиморфизм и анти-ангиогенезная терапия Download PDF

Info

Publication number
RU2013107095A
RU2013107095A RU2013107095/15A RU2013107095A RU2013107095A RU 2013107095 A RU2013107095 A RU 2013107095A RU 2013107095/15 A RU2013107095/15 A RU 2013107095/15A RU 2013107095 A RU2013107095 A RU 2013107095A RU 2013107095 A RU2013107095 A RU 2013107095A
Authority
RU
Russia
Prior art keywords
vegf
patient
treatment
antagonists
oligonucleotide
Prior art date
Application number
RU2013107095/15A
Other languages
English (en)
Other versions
RU2635525C2 (ru
Inventor
Брайан П. ШНАЙДЕР
Милан РАДОВИЧ
Джордж У. СЛЕДЖ
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2013107095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2013107095A publication Critical patent/RU2013107095A/ru
Application granted granted Critical
Publication of RU2635525C2 publication Critical patent/RU2635525C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/101—Taqman
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1. Способ прогнозирования высокой вероятности положительного эффекта от лечения антагонистами VEGF у пациента, включающий скрининг образцов, полученных от вышеуказанных пациентов для геномного полиморфизма в VEGF (-2578C/A), где пациент имеет повышенную вероятность положительного эффекта от лечения антагонистами VEGF, если соответствующий генотип содержит VEGF (-2578AA).2. Способ прогнозирования высокой вероятности положительного эффекта от лечения антагонистами VEGF у пациента, включающий скрининг образцов, полученных от вышеуказанных пациентов для геномного полиморфизма в VEGF (-1154G/A), где пациент имеет повышенную вероятность положительного эффекта от лечения антагонистами VEGF, если соответствующий генотип содержит VEGF (-1154AA).3. Способ по п.1 или 2, где указанным антагонистом VEGF является анти-VEGF антитело.4. Способ по п.3, где анти-VEGF антителом является бевацизумаб.5. Способ по п.1 или 2, где вышеуказанный пациент проходит лечение рака антагонистом VEGF.6. Способ по п.5, дополнительно включающий введение анти-неопластической композиции.7. Способ по п.5, где вышеуказанным раком является рак груди.8. Способ по п.5, где указанным антагонистом VEGF является анти-VEGF антитело.9. Способ по п.8, где указанным анти-VEGF антителом является бевацизумаб.10. Способ по п.8, дополнительно включающий введение анти-неопластической композиции.11. Набор для прогнозирования высокой вероятности положительного эффекта от лечения антагонистами VEGF у пациента, включающий первый олигонуклеотид и второй олигонуклеотид, специфичный для полиморфизма в VEGF, выбранный из группы, состоящей из VEGF (-2578C/A) и VEGF (-1154G/A).12. Набор по п.11, где первый олигонуклеотид и указанный второй олигон�

Claims (12)

1. Способ прогнозирования высокой вероятности положительного эффекта от лечения антагонистами VEGF у пациента, включающий скрининг образцов, полученных от вышеуказанных пациентов для геномного полиморфизма в VEGF (-2578C/A), где пациент имеет повышенную вероятность положительного эффекта от лечения антагонистами VEGF, если соответствующий генотип содержит VEGF (-2578AA).
2. Способ прогнозирования высокой вероятности положительного эффекта от лечения антагонистами VEGF у пациента, включающий скрининг образцов, полученных от вышеуказанных пациентов для геномного полиморфизма в VEGF (-1154G/A), где пациент имеет повышенную вероятность положительного эффекта от лечения антагонистами VEGF, если соответствующий генотип содержит VEGF (-1154AA).
3. Способ по п.1 или 2, где указанным антагонистом VEGF является анти-VEGF антитело.
4. Способ по п.3, где анти-VEGF антителом является бевацизумаб.
5. Способ по п.1 или 2, где вышеуказанный пациент проходит лечение рака антагонистом VEGF.
6. Способ по п.5, дополнительно включающий введение анти-неопластической композиции.
7. Способ по п.5, где вышеуказанным раком является рак груди.
8. Способ по п.5, где указанным антагонистом VEGF является анти-VEGF антитело.
9. Способ по п.8, где указанным анти-VEGF антителом является бевацизумаб.
10. Способ по п.8, дополнительно включающий введение анти-неопластической композиции.
11. Набор для прогнозирования высокой вероятности положительного эффекта от лечения антагонистами VEGF у пациента, включающий первый олигонуклеотид и второй олигонуклеотид, специфичный для полиморфизма в VEGF, выбранный из группы, состоящей из VEGF (-2578C/A) и VEGF (-1154G/A).
12. Набор по п.11, где первый олигонуклеотид и указанный второй олигонуклеотид могут быть использованы, чтобы амплифицировать часть VEGF гена, содержащего полиморфизм в VEGF, выбранный из группы, состоящей из VEGF (-2578C/A) и VEGF (-1154G/A).
RU2013107095A 2007-11-30 2013-02-18 Vegf полиморфизм и антиангиогенезная терапия RU2635525C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99161607P 2007-11-30 2007-11-30
US60/991,616 2007-11-30
US3869908P 2008-03-21 2008-03-21
US61/038,699 2008-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010126620/15A Division RU2482491C2 (ru) 2007-11-30 2008-11-26 Vegf полиморфизм и анти-ангиогенезная терапия

Publications (2)

Publication Number Publication Date
RU2013107095A true RU2013107095A (ru) 2014-08-27
RU2635525C2 RU2635525C2 (ru) 2017-11-13

Family

ID=40347982

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010126620/15A RU2482491C2 (ru) 2007-11-30 2008-11-26 Vegf полиморфизм и анти-ангиогенезная терапия
RU2013107095A RU2635525C2 (ru) 2007-11-30 2013-02-18 Vegf полиморфизм и антиангиогенезная терапия

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010126620/15A RU2482491C2 (ru) 2007-11-30 2008-11-26 Vegf полиморфизм и анти-ангиогенезная терапия

Country Status (23)

Country Link
US (1) US10031141B2 (ru)
EP (2) EP2506010B1 (ru)
JP (3) JP2011505145A (ru)
KR (2) KR101651796B1 (ru)
CN (2) CN104805203A (ru)
AT (1) ATE522809T1 (ru)
AU (1) AU2008334070B2 (ru)
BR (1) BRPI0819018A2 (ru)
CA (1) CA2705792A1 (ru)
CY (1) CY1112252T1 (ru)
DK (1) DK2220492T3 (ru)
ES (2) ES2547568T3 (ru)
HK (2) HK1153815A1 (ru)
HR (1) HRP20110867T1 (ru)
IL (1) IL205748A0 (ru)
MX (2) MX2010005868A (ru)
NZ (1) NZ628598A (ru)
PL (1) PL2220492T3 (ru)
PT (1) PT2220492E (ru)
RS (1) RS51987B (ru)
RU (2) RU2482491C2 (ru)
WO (1) WO2009073540A2 (ru)
ZA (1) ZA201003419B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030827B1 (ru) 2009-10-23 2018-10-31 Милленниум Фармасьютикалз, Инк. Анти-gcc антитело и его применения
WO2011146406A1 (en) * 2010-05-17 2011-11-24 University Of Southern California Germline polymorphisms in vegf predict clinical outcomes in cancer patients treated with sorafenib
MX343801B (es) * 2010-07-19 2016-11-23 F Hoffmann-La Roche Ag * Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
AU2012228544B2 (en) * 2011-02-23 2015-06-11 Sanofi Single nucleotide polymorphisms in the promoter of VEGFA gene and their use as predictive markers for anti-VEGF treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
MX2014002307A (es) * 2011-08-31 2014-08-26 Hoffmann La Roche Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.
RU2014110271A (ru) * 2011-08-31 2015-10-10 Ф. Хоффманн-Ля Рош Аг Восприимчивость к ингибиторам ангиогенеза
RS59370B1 (sr) * 2012-04-27 2019-11-29 Millennium Pharm Inc Molekuli anti-gcc antitela i njihova upotreba u ispitivanju osetljivosti na gcc-ciljanu terapiju
US10456470B2 (en) * 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CN106471132B (zh) 2014-06-18 2020-09-22 东丽株式会社 肺癌的检测试剂盒或装置以及检测方法
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
JP2018507627A (ja) * 2015-01-29 2018-03-15 華為技術有限公司Ｈｕａｗｅｉ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏ．，Ｌｔｄ． 無線ベアラ再構成方法、無線ベアラ確立方法、ユーザ機器、および基地局
CN108913772B (zh) * 2018-06-15 2020-04-03 上海思路迪生物医学科技有限公司 基于捕获测序的bMSI检测技术

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US6455249B1 (en) 1997-09-10 2002-09-24 National Institutes Of Health Method of amplifying DNA and RNA mismatch cleavage products
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
JP2007020563A (ja) 2005-06-13 2007-02-01 Sutaagen:Kk 糖尿病網膜症発症及び／又は進展リスクの診断方法
RU2287158C1 (ru) * 2005-07-07 2006-11-10 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ прогнозирования развития гипертонической болезни по генетическим факторам риска
CA2615636A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
US20070218487A1 (en) * 2006-03-03 2007-09-20 University Of Southern California Genetic markers for predicting disease and treatment outcome
WO2007103814A2 (en) * 2006-03-03 2007-09-13 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection

Also Published As

Publication number Publication date
EP2506010A2 (en) 2012-10-03
JP2015171388A (ja) 2015-10-01
HK1213295A1 (zh) 2016-06-30
NZ628598A (en) 2016-09-30
MX2010005868A (es) 2010-12-21
AU2008334070A1 (en) 2009-06-11
KR20100126651A (ko) 2010-12-02
ES2372236T3 (es) 2012-01-17
EP2220492B1 (en) 2011-08-31
IL205748A0 (en) 2010-11-30
PL2220492T3 (pl) 2012-01-31
RU2482491C2 (ru) 2013-05-20
WO2009073540A3 (en) 2009-08-13
HK1153815A1 (en) 2012-04-05
JP5797288B2 (ja) 2015-10-21
PT2220492E (pt) 2011-12-16
ATE522809T1 (de) 2011-09-15
RS51987B (en) 2012-02-29
MX340668B (es) 2016-07-20
DK2220492T3 (da) 2011-12-12
JP2014094014A (ja) 2014-05-22
KR101651690B1 (ko) 2016-08-26
KR20150080020A (ko) 2015-07-08
KR101651796B1 (ko) 2016-08-26
BRPI0819018A2 (pt) 2015-05-05
EP2506010A3 (en) 2013-01-09
RU2635525C2 (ru) 2017-11-13
EP2220492A2 (en) 2010-08-25
ES2547568T3 (es) 2015-10-07
US20110176993A1 (en) 2011-07-21
CY1112252T1 (el) 2015-12-09
CN102016579A (zh) 2011-04-13
EP2506010B1 (en) 2015-06-17
JP2011505145A (ja) 2011-02-24
CN104805203A (zh) 2015-07-29
HRP20110867T1 (hr) 2012-01-31
ZA201003419B (en) 2012-09-26
US10031141B2 (en) 2018-07-24
AU2008334070B2 (en) 2015-04-16
CA2705792A1 (en) 2009-06-11
CN102016579B (zh) 2015-04-08
WO2009073540A2 (en) 2009-06-11
RU2010126620A (ru) 2012-01-10

Similar Documents

Publication Publication Date Title
RU2013107095A (ru) Vegf полиморфизм и анти-ангиогенезная терапия
Razmkhah et al. Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma
Sohn et al. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer
KR20160009582A (ko) 크론병과 연관된 tnfsf15와 dcr3의 변이체
RU2013131239A (ru) Улучшенный способ и набор для определения тяжести и прогрессирования периодонтального заболевания
US20170065590A1 (en) Method of Treating Cancer
Kadkhodazadeh et al. Receptor activator of nuclear factor kappa-B gene polymorphisms in Iranian periodontitis and peri-implantitis patients
WO2016008014A1 (en) Method of predicting rapid progression of fibrosis and therapy and reagents therefor
CN101033489A (zh) 一种与原发性肝癌相关的cdc6基因的单核苷酸多态位点及其应用
ATE500275T1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
WO2006018290A3 (de) Verfahren und kit zur diagnose einer krebserkrankung verfahren zum feststellen des ansprechens eines patienten auf die behandlung einer krebserkrankung, therapeutikum zur prophylaxe oder behandlung einer krebserkrankung
Linkowska et al. Searching for association of the CAG repeat polymorphism in the mitochondrial DNA polymerase gamma gene (POLG) with colorectal cancer
KR20120031734A (ko) 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법
RU2014110270A (ru) Способ прогнозирования риска гипертензии, связанной с антиангиогенной терапией
El-Bendary et al. Epidermal Growth Factor Genetic Polymorphism and Its Circulating Serum Level Predict the Risk of Hepatocellular Carcinoma in Egyptian Patients with HCV (Genotype-4)-Related Cirrhosis
CN1786188A (zh) 检测载脂蛋白e基因型的方法和试剂盒
Malla et al. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer
CN101487054B (zh) 猪免疫力相关分子标记克隆及应用
Jin et al. Polymorphism of the VEGF gene and its association with growth traits in four goat breeds
Zavala-Cerna et al. Research Article Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report
AU2017270496A1 (en) Determination of genetic predisposition to aggressive prostate cancer
Sharafi et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common...